DEALS
Zhong Lun Assists Medprin to List on ChiNext
Zhong Lun Assists Medprin to List on ChiNext
On July 26, 2021, Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. (“Medprin", stock code: 301033) launched its initial public offering and went public on ChiNext of the Shenzhen Stock Exchange. Medprin is the first company to apply for listing on and complete registration with the exchange under the revamped listing standards of ChiNext.
Zhong Lun acted as legal counsel for the offering. Having provided legal services for the client’s previous rounds of financing, regulation of its employee stock ownership, and the entire process of its listing, Zhong Lun has won recognition from the client for professionalism and first-class service. The mandate was led by the firm’s equity partner Xiaoyan Zhang and non-equity partner Qiaofen Sun. Members of the team also included Si Zeng and other associates.
Medprin specializes in research, development, and manufacturing of high-end medical devices in combination with the characteristics of artificial synthetic materials, with a focus on tissue regenerative implanted medical devices. It is currently the only Chinese neurosurgery company capable of manufacturing a full range of main implanted medical devices required for craniotomy, such as novel dural patch, absorbable hemostat, and cranio-maxillofacial repair products. At the same time, Medprin is expanding the application of its products to multiple disciplines in response to clinical needs, using multiple technology platforms. With all these efforts, Medprin is committed to growing into the world’s leading player in the field of implanted medical devices and providing great products to patients across the globe.
